Hepatocellular adenomas. J Exp Med 2011, 208:1359366. 6. Sorkin A, von Zastrow M: Endocytosis and signalling: intertwining molecular networks. Nat Rev Mol Cell Biol 2009, 10:60922. 7. Marty C, Chaligne R, Lacout C, Constantinescu SN, Vainchenker W, Villeval JL: Ligand-independent thrombopoietin PPARβ/δ Activator medchemexpress mutant receptor requires cell surface localization for endogenous activity. J Biol Chem 2009, 284:117811791. 8. Schmidt-Arras D, B mer SA, Koch S, M ler JP, Blei L, Cornils H, Bauer R, Korasikha S, Thiede C, B mer FD: Anchoring of FLT3 within the endoplasmic reticulum alters signaling top quality. Blood 2009, 113:3568576. 9. Dittrich A, Quaiser T, Khouri C, G tz D, M nigmann M, Schaper F: Model-driven experimental evaluation from the function of SHP-2 in IL-6-induced Jak/STAT signaling. Mol Biosyst 2012, eight:2119134. ten. Gerhartz C, Dittrich E, Stoyan T, Rose-John S, Yasukawa K, Heinrich Computer, Graeve L: Biosynthesis and half-life of your interleukin-6 receptor and its signal transducer gp130. Eur J Biochem 1994, 223:26574. 11. Stahl N, Farrugella TJ, Boulton TG, Zhong Z, Darnell JE Jr, Yancopoulos GD: Choice of STATs as well as other substrates specified by modular tyrosine-based motifs in cytokine receptors. Science 1995, 267:1349353. 12. Gerhartz C, Heesel B, Sasse J, Hemmann U, Landgraf C, Schneider-Mergener J, Horn F, Heinrich Computer, Graeve L: Differential activation of acute phase response factor/STAT3 and STAT1 through the cytoplasmic domain of your interleukin-6 signal transducer gp130. 1. Definition of a novel phosphotyrosine motif mediating STAT1 activation. J Biol Chem 1996, 271:129912998. 13. Schmitz J, Dahmen H, Grimm C, Gendo C, M ler-Newen G, Heinrich Pc, Schaper F: The cytoplasmic tyrosine motifs in full-length gp130 have different roles in IL-6 signal transduction. J Immunol 2000, 164:84854. 14. Poussin K, Pilati C, Couchy G, Calderaro J, Bioulac-Sage P, Bacq Y, PDE3 Modulator Compound Paradis V, Leteurtre E, Sturm N, Ramos J, Guettier C, Bardier-Dupas A, Boulai A, Wendum D, Selves J, Izard T, Nault JC, Zucman-Rossi J: Biochemical and functional analyses of gp130 mutants unveil JAK1 as a novel therapeutic target in human inflammatory hepatocellular adenoma. Oncoimmunology 2013, two:e27090. 15. Thiel S, Dahmen H, Martens A, M ler-Newen G, Schaper F, Heinrich Computer, Graeve L: Constitutive internalization and association with adaptor protein-2 from the interleukin-6 signal transducer gp130. FEBS lett 1998, 441:23134. 16. Damke H, Baba T, Warnock DE, Schmid SL: Induction of mutant dynamin particularly blocks endocytic coated vesicle formation. J Cell Biol 1994, 127:91534. 17. Wijdenes J, Heinrich Pc, M ler-Newen G, Roche C, Zong-Jiang G, Clement C, Klein B: Interleukin-6 signal transducer gp130 has precise binding web-sites for various cytokines as determined by antagonistic and agonistic anti-gp130 monoclonal antibodies. Eur J Immunol 1995, 25:3474481.Cells had been grown on poly-l-lysine coated coverslips. Fixation of cells has been described previously [19]. Confocal imaging was performed having a Zeiss LSM 710 confocal microscope (Zeiss, Jena, Germany). mCherry fluorescence was detected making use of the 561 nm laser plus a 578-696 nm bandpass filter. The cells were examined with a Zeiss LD C-apochromat 401.1 water objective. Confocal images represent confocal slices of about 1 m.Additional filesAdditional file 1: Effect of intracellular retention of de novo synthesized CAgp130 on general receptor expression. T-REx-293-WTgp130-YFP and T-REx-293-CAgp130-YFP had been left untreated or expression was induce.
Posted inUncategorized